¼¼°èÀÇ È÷¿À½Å(Hyoscine) ½ÃÀå ±Ô¸ð Á¶»ç : À¯Çüº°, Åõ¿© ¹æ¹ýº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)
Global Hyoscine Market Size study, by Type (Hyoscine Butyl Bromide, Hyoscine Hydrobromide), by Mode of Administration (Oral, Patches, Injections) and Regional Forecasts 2022-2032
»óǰÄÚµå
:
1735845
¸®¼Ä¡»ç
:
Bizwit Research & Consulting LLP
¹ßÇàÀÏ
:
2025³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 285 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
È÷¿À½Å ¼¼°è ½ÃÀåÀº 2023³â¿¡ ¾à 4¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç, ¿¹Ãø ±â°£ 2024³âºÎÅÍ 2032³â±îÁö 4.80%ÀÇ ¾ÈÁ¤µÈ CAGR·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
½ºÄÚÆú¶ó¹ÎÀ̶ó°íµµ ºÒ¸®´Â È÷¿À½ÅÀº °·ÂÇÑ Ç×Äݸ°Á¦·Î ¸Ö¹Ì, ¸Þ½º²¨¿ò, À§Àå ¹× ºñ´¢±â ÁúȯÀ¸·Î ÀÎÇÑ º¹ºÎ °æ·Ã µîÀÇ ¿¹¹æ ¹× Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ±¤¹üÀ§ÇÑ ÀÓ»óÀû À¯¿ë¼ºÀº Àú·ÅÇÑ °¡°Ý°ú °·ÂÇÑ ¾ÈÀü¼º ÇÁ·ÎÆÄÀϰú °áÇÕÇÏ¿© ¼±Áø±¹°ú ½ÅÈï±¹ ½ÃÀå ¸ðµÎ¿¡¼ Áö¼ÓÀûÀÎ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. È÷¿À½ÅÀº °æ±¸¿ë Á¤Á¦, °æÇÇ¿ë ÆÐÄ¡, ÁÖ»çÁ¦ µî ´Ù¾çÇÑ Á¦ÇüÀ¸·Î Á¦°øµÇ¸ç, ƯÈ÷ ¿©Çà ÀÇ·á, ¿ÏÈ Ä¡·á, ¼ö¼ú ÀüÈÄ Ä¡·á µî ´Ù¾çÇÑ Ä¡·á ¼ö¿ä¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.
½ÃÀåÀÇ ¼ºÀå ±ËÀûÀº Àü ¼¼°è ¿©Çà Ȱµ¿ÀÇ È°¼ºÈ¿Í ¸Ö¹Ì °ü¸®¿¡ ´ëÇÑ ÀνÄÀÇ Áõ°¡¿¡ Å©°Ô ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ƯÈ÷ À§Àå Àå¾Ö¿Í ÆòȰ±Ù °æ·Ã¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸´Â È÷¿À½Å°ú °°Àº Ç×°æ·ÃÁ¦ ¼ö¿ä¿¡ Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù. Áö¼ÓÇü ÆÐÄ¡ ¹× ¹æÃâ Á¦¾î ÁÖ»çÁ¦¿Í °°Àº ¾à¹°Àü´ÞÀÇ Çõ½ÅÀº Ä¡·á ¼øÀÀµµ¿Í ȯÀÚÀÇ ÆíÀǼºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ±×·¯³ª Á¹À½°ú °¥Áõ°ú °°Àº ºÎÀÛ¿ë°ú ´ëü ¿ä¹ýÀÇ °¡¿ë¼º°ú °°Àº ¹®Á¦´Â Æò°¡ ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ¾î´À Á¤µµ ¾ïÁ¦ÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÀÓ»ó ¼ö¿ä¿Í ÇÔ²² Á¦¾à»çµéÀº ½ÃÀå °æÀï·ÂÀ» °ÈÇϱâ À§ÇØ Á¦³×¸¯ ÀǾàǰ Ãâ½Ã ¹× ƯÇã ¿¬ÀåÀ» ÅëÇØ Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ Àû±ØÀûÀ¸·Î È®ÀåÇϰí ÀÖ½À´Ï´Ù. È÷¿À½ÅÀº º´¿ø°ú ¼Ò¸ÅÁ¡ ȯ°æ ¸ðµÎ¿¡¼ ÀûÀÀ·ÂÀÌ ÀÖÀ¸¸ç, ƯÈ÷ ºñħ½ÀÀû ºÎÂøÁ¦¶ó´Â Á¡¿¡¼ ºñó¹æ Ä¡·á ºÐ¾ß¿¡¼ ±× °ü·Ã¼ºÀ» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù. ºñħ½ÀÀû ¾à¹°Àü´Þ ¹× ÀÚ°¡ Åõ¾àÀ¸·Î ÀüȯÇÏ´Â Ãß¼¼´Â ƯÈ÷ °Ç° ÀǽÄÀÌ ³ôÀº Áö¿ª¿¡¼ °æÇÇÈí¼ö¼º ÆÐÄ¡¿¡ ´ëÇÑ ¼±È£µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ÁÖ»çÁ¦´Â ÀÀ±Þ »óȲÀ̳ª ¼ö¼ú ÀüÈÄ¿¡ ½Å¼ÓÇÑ ¾àÈ¿ ¹ßÇöÀ» º¸ÀåÇϱâ À§ÇØ ¿©ÀüÈ÷ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.
Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ³ôÀº ¸Ö¹Ì À¯º´·ü, ¼±ÁøÈµÈ ÀÇ·á ÀÎÇÁ¶ó, Àß ±¸ÃàµÈ À¯Åë¸ÁÀ» ¹ÙÅÁÀ¸·Î ÇöÀç ºÏ¹Ì°¡ ¼¼°è È÷¿À½Å ½ÃÀå¿¡¼ Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. À¯·´Àº °·ÂÇÑ ÀǾàǰ ¿¬±¸°³¹ß°ú ¿©Çà°ú °ü·ÃµÈ °Ç° »óÅ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ±ÞÁõÇÏ´Â Àα¸ ±â¹Ý, °¡Ã³ºÐ ¼Òµæ Áõ°¡, ÇコÄɾî Á¦Ç°¿¡ ´ëÇÑ Á¢±Ù¼º È®´ë¿¡ ÈûÀÔ¾î ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àεµ, Áß±¹, ÀϺ» µîÀÇ ±¹°¡¿¡¼´Â À§Àå ÁúȯÀÇ Áõ°¡¿Í Á¦³×¸¯ ÀǾàǰ »ê¾÷ÀÇ È®´ë·Î ÀÎÇØ 󹿷üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«´Â ÀÇ·á °³Çõ°ú ¼Ò¸Å ¾à±¹ ³×Æ®¿öÅ©ÀÇ È®Àå¿¡ ÈûÀÔ¾î Á¡ÁøÀûÀ¸·Î ¹ßÀüÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¼°èÀÇ È÷¿À½Å ½ÃÀå : ÁÖ¿ä ¿ä¾à
- ¼¼°èÀÇ È÷¿À½Å ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø(2022-2032³â)
- Áö¿ªº° °³¿ä
- ºÎ¹®º° °³¿ä
- ÁÖ¿ä µ¿Çâ
- °æ±âÈÄÅðÀÇ ¿µÇâ
- ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È°ú °á·Ð
Á¦2Àå ¼¼°èÀÇ È÷¿À½Å ½ÃÀå : Á¤ÀÇ¿Í Á¶»ç °¡Á¤
- Á¶»ç ¸ñÀû
- ½ÃÀå Á¤ÀÇ
- Á¶»ç °¡Á¤
- Æ÷ÇÔ°ú Á¦¿Ü
- Á¦ÇÑ»çÇ×
- °ø±ÞÃø ºÐ¼®
- °¡¿ë¼º
- ÀÎÇÁ¶ó
- ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
- ½ÃÀå °æÀï
- °æÁ¦¼º(¼ÒºñÀÚÀÇ °üÁ¡)
- ¼ö¿äÃø ºÐ¼®
- ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
- ±â¼úÀû Áøº¸
- ģȯ°æ
- ¼ÒºñÀÚ Àǽİú ¼ö¿ë
- Á¶»ç ¹æ¹ý
- Á¶»ç ´ë»ó ¿¬µµ
- ÅëÈ È¯»êÀ²
Á¦3Àå ¼¼°èÀÇ È÷¿À½Å ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
- ½ÃÀå ±âȸ
Á¦4Àå ¼¼°èÀÇ È÷¿À½Å ½ÃÀå »ê¾÷ ºÐ¼®
- Porter's Five Forces ¸ðµ¨
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- ±¸¸ÅÀÚÀÇ ±³¼··Â
- ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀï ±â¾÷ °£ÀÇ °æÀï °ü°è
- Porter's Five Forces ¸ðµ¨·ÎÀÇ ¹Ì·¡ÁöÇâÀû Á¢±Ù¹ý
- Porter's Five ForcesÀÇ ¿µÇ⠺м®
- PESTEL ºÐ¼®
- Á¤Ä¡Àû
- °æÁ¦Àû
- »çȸÀû
- ±â¼úÀû
- ¹ýÀû
- ȯ°æÀû
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- µð½º·´¼Ç µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ °üÁ¡
- ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È°ú °á·Ð
Á¦5Àå ¼¼°èÀÇ È÷¿À½Å ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : À¯Çüº°, 2022-2032³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ È÷¿À½Å ½ÃÀå : À¯Çü ¸ÅÃâ µ¿Ç⠺м®, 2022³â ¹× 2032³â
- È÷¿À½Å ºê·ÒÈºÎÆ¿
- È÷¿À½Å ºê·Òȼö¼Ò»ê¿°
Á¦6Àå ¼¼°èÀÇ È÷¿À½Å ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : Åõ¿© ¹æ¹ýº°, 2022-2032³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ È÷¿À½Å ½ÃÀå : °ü¸® ¸ðµå ¸ÅÃâ µ¿Ç⠺м®, 2022³â ¹× 2032³â
Á¦7Àå ¼¼°èÀÇ È÷¿À½Å ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : Áö¿ªº°, 2022-2032³â
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ÀÌÅ»¸®¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- È£ÁÖ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ¸ß½ÃÄÚ
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦8Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc
- Baxter International Inc.
- ÁÖ¿ä ½ÃÀå Àü·«
- ±â¾÷ °³¿ä
- Boehringer Ingelheim International GmbH
- ÁÖ¿ä Á¤º¸
- °³¿ä
- À繫(µ¥ÀÌÅÍ °¡¿ë¼º¿¡ µû¶ó ´Ù¸§)
- Á¦Ç° °³¿ä
- ½ÃÀå Àü·«
- GlaxoSmithKline plc
- Baxter International Inc.
- Alchem International Pvt. Ltd.
- Novartis AG
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Bayer AG
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Abbott Laboratories
- Hikma Pharmaceuticals PLC
- Zydus Lifesciences Limited
Á¦9Àå Á¶»ç °úÁ¤
- Á¶»ç °úÁ¤
- µ¥ÀÌÅÍ ¸¶ÀÌ´×
- ºÐ¼®
- ½ÃÀå ¿¹Ãø
- °ËÁõ
- ÃâÆÇ
- Á¶»ç ¼Ó¼º
KSM
¿µ¹® ¸ñÂ÷
The Global Hyoscine Market is valued at approximately USD 0.41 billion in 2023 and is anticipated to expand at a steady CAGR of 4.80% over the forecast period 2024-2032. Hyoscine, also referred to as scopolamine, is a potent anticholinergic drug extensively employed to prevent and treat motion sickness, nausea, and abdominal cramps caused by gastrointestinal and urological disorders. Its widespread clinical utility, coupled with affordability and a strong safety profile, has contributed to its continued demand across both developed and emerging markets. With a variety of formulations including oral tablets, transdermal patches, and injectable solutions, hyoscine caters to a wide range of therapeutic needs, particularly in travel health, palliative care, and perioperative medicine.
The market's growth trajectory is significantly influenced by the rising global travel activity and increasing awareness of motion sickness management. Moreover, the elderly population, which is particularly susceptible to gastrointestinal disturbances and smooth muscle spasms, contributes meaningfully to the demand for antispasmodic medications like hyoscine. Innovation in drug delivery, such as long-acting patches and controlled-release injectables, has augmented treatment adherence and patient comfort. However, challenges such as drug side effects, including drowsiness and dry mouth, along with availability of alternative therapies, might temper the market's growth to an extent during the assessment period.
In parallel with clinical demand, pharmaceutical companies are proactively expanding their product portfolios through generic launches and patent extensions to bolster market competitiveness. Hyoscine's adaptability in both hospital and retail settings-particularly for its non-invasive patch application-has further pushed its relevance among non-prescription treatments. The trend of shifting toward non-invasive drug delivery and self-administration is giving rise to an increased preference for transdermal patches, particularly in regions with high consumer health awareness. Injections remain crucial in emergency and perioperative settings, ensuring rapid onset of action.
Regionally, North America currently commands a major share of the Global Hyoscine Market, driven by the high prevalence of motion sickness, advanced healthcare infrastructure, and well-established distribution networks. Europe closely follows, benefiting from strong pharmaceutical R&D and heightened awareness of travel-related health conditions. The Asia Pacific region is poised for the most significant growth during the forecast period, propelled by a burgeoning population base, increasing disposable income, and expanding accessibility to healthcare products. Countries such as India, China, and Japan are witnessing higher prescription rates owing to rising gastrointestinal disorders and an expanding generic pharmaceutical industry. Latin America and the Middle East & Africa are gradually progressing, supported by healthcare reforms and a growing retail pharmacy network.
Major market player included in this report are:
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc
- Baxter International Inc.
- Alchem International Pvt. Ltd.
- Novartis AG
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Bayer AG
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Abbott Laboratories
- Hikma Pharmaceuticals PLC
- Zydus Lifesciences Limited
The detailed segments and sub-segment of the market are explained below:
By Type
- Hyoscine Butyl Bromide
- Hyoscine Hydrobromide
By Mode of Administration
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- South Africa
- RoMEA
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
Table of Contents
Chapter 1. Global Hyoscine Market Executive Summary
- 1.1. Global Hyoscine Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Type
- 1.3.2. By Mode of Administration
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Hyoscine Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory Frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Hyoscine Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Rising Prevalence of Motion Sickness and Gastrointestinal Disorders
- 3.1.2. Growth in Global Travel and Tourism
- 3.1.3. Expansion of Elderly Population Requiring Antispasmodic Therapy
- 3.2. Market Challenges
- 3.2.1. Side-Effect Profile Including Drowsiness and Dry Mouth
- 3.2.2. Availability of Alternative Antiemetic and Antispasmodic Therapies
- 3.2.3. Regulatory Constraints on Anticholinergic Use
- 3.3. Market Opportunities
- 3.3.1. Innovation in Transdermal Patch and Controlled-Release Formulations
- 3.3.2. Expansion of Over-the-Counter Distribution Channels
- 3.3.3. Penetration into Emerging Markets with Growing Healthcare Access
Chapter 4. Global Hyoscine Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Hyoscine Market Size & Forecasts by Type 2022-2032
- 5.1. Segment Dashboard
- 5.2. Global Hyoscine Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 5.2.1. Hyoscine Butyl Bromide
- 5.2.2. Hyoscine Hydrobromide
Chapter 6. Global Hyoscine Market Size & Forecasts by Mode of Administration 2022-2032
- 6.1. Segment Dashboard
- 6.2. Global Hyoscine Market: Mode of Administration Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 6.2.1. Oral
- 6.2.2. Patches
- 6.2.3. Injections
Chapter 7. Global Hyoscine Market Size & Forecasts by Region 2022-2032
- 7.1. North America Hyoscine Market
- 7.1.1. U.S. Hyoscine Market
- 7.1.1.1. Type breakdown size & forecasts, 2022-2032
- 7.1.1.2. Mode of Administration breakdown size & forecasts, 2022-2032
- 7.1.2. Canada Hyoscine Market
- 7.2. Europe Hyoscine Market
- 7.2.1. U.K. Hyoscine Market
- 7.2.2. Germany Hyoscine Market
- 7.2.3. France Hyoscine Market
- 7.2.4. Spain Hyoscine Market
- 7.2.5. Italy Hyoscine Market
- 7.2.6. Rest of Europe Hyoscine Market
- 7.3. Asia-Pacific Hyoscine Market
- 7.3.1. China Hyoscine Market
- 7.3.2. India Hyoscine Market
- 7.3.3. Japan Hyoscine Market
- 7.3.4. Australia Hyoscine Market
- 7.3.5. South Korea Hyoscine Market
- 7.3.6. Rest of Asia Pacific Hyoscine Market
- 7.4. Latin America Hyoscine Market
- 7.4.1. Brazil Hyoscine Market
- 7.4.2. Mexico Hyoscine Market
- 7.4.3. Rest of Latin America Hyoscine Market
- 7.5. Middle East & Africa Hyoscine Market
- 7.5.1. Saudi Arabia Hyoscine Market
- 7.5.2. South Africa Hyoscine Market
- 7.5.3. Rest of Middle East & Africa Hyoscine Market
Chapter 8. Competitive Intelligence
- 8.1. Key Company SWOT Analysis
- 8.1.1. Boehringer Ingelheim International GmbH
- 8.1.2. GlaxoSmithKline plc
- 8.1.3. Baxter International Inc.
- 8.2. Top Market Strategies
- 8.3. Company Profiles
- 8.3.1. Boehringer Ingelheim International GmbH
- 8.3.1.1. Key Information
- 8.3.1.2. Overview
- 8.3.1.3. Financial (Subject to Data Availability)
- 8.3.1.4. Product Summary
- 8.3.1.5. Market Strategies
- 8.3.2. GlaxoSmithKline plc
- 8.3.3. Baxter International Inc.
- 8.3.4. Alchem International Pvt. Ltd.
- 8.3.5. Novartis AG
- 8.3.6. Mylan N.V.
- 8.3.7. Sun Pharmaceutical Industries Ltd.
- 8.3.8. Pfizer Inc.
- 8.3.9. Bayer AG
- 8.3.10. Sanofi S.A.
- 8.3.11. Teva Pharmaceutical Industries Ltd.
- 8.3.12. Aurobindo Pharma
- 8.3.13. Abbott Laboratories
- 8.3.14. Hikma Pharmaceuticals PLC
- 8.3.15. Zydus Lifesciences Limited
Chapter 9. Research Process
- 9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
- 9.2. Research Attributes
°ü·ÃÀÚ·á